Utilization of Fluorescence Polarization and Time Resolved Fluorescence Resonance Energy Transfer Assay Formats for SAR Studies: Src Kinase as a Model System

Abstract

High-throughput screening (HTS), a major component of lead identification, often utilizes fluorescence-based assay technologies. For example, HTS kinase assays are formatted using a variety of fluorescence-based assay technologies including, but not limited to, dissociation enhanced lanthanide fluoroimmunoassay (DELFIA^®), time-resolved fluorescence resonance energy transfer (TR-FRET), and fluorescence polarization (FP). These assays offer tremendous advantages such as a nonradioactive format, ease of automation, and excellent reproducibility. Fluorescence-based assays frequently used for lead identification can also be useful for structure activity relationship (SAR) studies during lead optimization. An important issue when assessing an assay to be used for SAR is the ability of the assay to discriminate high-affinity small molecule inhibitors (pM-nM) from low-affinity inhibitors (μM-mM). The purpose of this study was to utilize HTS-friendly assay formats for SAR by developing TR-FRET, FP, and DELFIA^® assays measuring Src kinase activity and to define the theoretical lower limit of small molecule inhibitor detection achievable with these assay formats. The authors show that 2 homogeneous assay formats, TR-FRET and FP, allowed for the development of Src kinase assays with a lower limit of detection of K_i = 0.01nM. This study indicates that assay technologies typically used for HTS can be used during lead optimization by providing quantitative measurements of compound activity critical to driving SAR studies.

Keywords

lead optimization TR-FRET FP SAR HTS DELFIA Src kinase

References

1. Hunter T : Signaling—2000 and beyond. Cell 2000;100:113-127.

2. Machida E , Mayer BJ , Nollau P : Profiling the global tyrosine phosphorylation state. Mol Cell Proteomics 2003;2:215-233.

3. Pawson T : Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002;38:3-10.

4. Laird D , Cherrington J : Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs 2003;12:51-64.

5. Allgayer H , Boyd D , Heiss M : Activation of Src kinase in primary colorectal carcinoma. Anindicator of poor clinical prognosis. Cancer 2002;94:344-351.

6. Marth JD , Peet R , Krebs EG , Perlmutter RM : A lymphocyte-specific proteintyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA. Cell 1985;43:393-404.

7. Lakowicz J : Principles of fluorescence spectroscopy. New York: Kluwer Academic/Plenum, 1999.

8. Owicki J : Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J Biomol Screen 2000;5:297-306.

9. Morrison LE : Time resolved detection of energy transfer: theory and application to immunoassays. Anal Biochem 1988;174:101-120.

10.

10. Hemmila I , Webb S : Time-resolved fluorometry: an overview of the labels and core technologies for drug screening applications. Drug Discov Today 1997;2:373-381.

11.

11. Zhang J-H , Chung TDY , Oldenburg KR : A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.

12.

12. Edison A , Barker S , Kassel D , Luther M , Knight W : Exploration of the sequence specificity of pp60 c-Src tyrosine kinase. J Biol Chem 1995;270:27112-27115.

13.

13. Seethala R , Menzel R : A homogenous, fluorescence polarization assay for Src-family tyrosine kinases. Anal Biochem 1997;253:210-218.

14.

14. Ohmi N , Wingfield J , Yazawa H , Inagaki O : Development of a homogenous time-resolved fluorescence assay for high throughput screening to identify lck inhibitors: comparison with scintillation proximity assay and streptavidincoated plate assay. J Biomol Screen 2000;5:463-470.

15.

15. Bader B , Butt E , Palmetshofer A , Walter U , Jarchan T , Drueckes P : A cGMP dependent protein kinase assay for HTS based on TR-FRET. J Biomol Screen 2001;6:255-264.

16.

16. Bollini S , Herbst J , Gaughan G , Verdoorn T , Ditta J , Dubowchik G , et al: High throughput fluorescence polarization method for identification of FKBP12 ligands. J Biomol Screen 2002;7:526-530.

17.

17. Kolb A , Kaplita P , Hayes D , Park Y , Pernell C , Major J , et al: Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Discov Today 1993;3:333-432.

18.

18. Braun S , Raymon W , Racker E : Synthetic tyrosine polymers as substrates and inhibitors of tyrosine-specific protein kinases. J Biol Chem 1984;4:2051-2054.

19.

19. Cole P , Burn P , Takacs B , Walsh C : Evaluation of the catalytic mechanism of recombinant human Csk (C-terminal Src kinase) using nucleotide analogs and viscosity effects. J Biol Chem 1994;269:30880-30887.

20.

20. Sills M , Weiss D , Pham Q , Schweitzer R , Wu X , Wu J : Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening. J Biomol Screen 2002;7:191-199.

21.

21. Hanke J , Gardner J , Dow R , Changelian P , Brissette W , Weringer E , et al: Discovery of a novel, potent and Src family-selective tyrosine kinase inhibitor. J Biol Chem 1996;271:695-701.

22.

22. Cheng Y , Prusoff W : Relationship between the inhibition constant (Ki)and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharm 1973;22:3099-3108.